ADJUVANT COMPARISON AND CHARACTERIZATION

佐剂比较和表征

• 批准号: 10703820
• 负责人: PHILIP FELGNER
• 金额: $ 135万
• 依托单位: UNIVERSITY OF CALIFORNIA-IRVINE
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10703820
• 关键词: Adjuvant; Chlamydia muridarum; Coxiella burnetii; Data Analyses; Fingerprint; Goals; Human; Immune; Immunologics; Influenza; Mus; Organoids; Side; Tissues; Tonsil; Vaccine Antigen; Work; adaptive immune response; clinically relevant; data management; flu; programs

The goal of the Adjuvant Comparison and Characterization (ACC) program is to support side-by-side comparison of adjuvants in combination with clinically relevant vaccine/antigen platforms, and to establish both systemic and tissue-specific immunological profiles (“immune fingerprints”) of adjuvants that work through different mechanisms in the context of Influenza (flu), Chlamydia muridarum (Cm), and Coxiella burnetii (Cb).

佐剂比较和表征（ACC）计划的目标是支持佐剂与临床相关疫苗/抗原平台的并行比较，并建立佐剂的全身和组织特异性免疫学特征（“免疫指纹”），这些佐剂在流感（flu）、鼠衣原体（Cm）和贝氏柯克斯体（Cb）的背景下通过不同机制发挥作用。